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ABSTRACT This study aimed to gain insight into the impact of lung conditions on smoking behaviour
and smoking cessation, and identify recommendations for smoking cessation and professional–patient
communications. The study was led by the European Lung Foundation in collaboration with the European
Respiratory Society Task Force on “Statement on smoking cessation on COPD and other pulmonary
diseases and in smokers with comorbidities who find it difficult to quit”.
A web-based observational cross-sectional questionnaire was developed from a patient-centered
literature review. Topics covered were: cohort characteristics; perspectives on smoking cessation;
interactions with healthcare professionals; and recommendations to improve cessation outcomes.
The questionnaire was disseminated via existing patient and professional networks and social media
channels. The survey was available online for a period of 4 months in 16 languages. The data were
analysed as a whole, not by country, with thematic analysis of the open responses.
Common characteristics were: male (54%); age 40–55 years (39%); 11–20 cigarettes a day (39%); smokes
within 30 min of waking (61%); and has made 1–5 cessation attempts in the previous 12 months (54%).
59% had tried cessation treatments, but, of these, 55% had not found any treatments helpful.
Recommendations were: earlier intervention; discussion of the patient’s smoking beliefs, behaviours and
motivation; giving constructive advice; understanding addiction; informed decision-making; and treatment
options. Areas for new and further research have been highlighted through exploring the smoking
cessation perspectives and recommendations of people with lung conditions in Europe who smoke.
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Smoking leads to >650000 premature deaths in Europe every year, with estimates that ∼1 billion people
worldwide will be killed by tobacco in the 21st century [1]. Smoking is the leading cause of chronic
obstructive pulmonary disease (COPD), with projections that, by 2020, COPD will have become the third
cause of death and the fifth cause of disability worldwide [2]. Although only 15% of the world’s population
live in Europe, it carries nearly a third of the burden of tobacco-related disease, with a huge impact on
national economies and healthcare services. To combat this growing health crisis, effective
smoking-cessation services, delivered and signposted by healthcare professionals (HCPs) are essential [1, 3].
The number of premature deaths and the impact of lung disease on quality of life and symptom control
can be reduced by raising awareness of the value of smoking cessation to people with a lung condition,
such as COPD, asthma and lung cancer [2–5]. For example, smoking cessation is the only effective means
of controlling the progression of COPD [2, 3, 6, 7]; however, ∼40% of people with COPD continue to
smoke [3, 8]. HCPs are in a position to engage with this population, but little research has been conducted
into the smoking cessation behaviours and perspectives of people with lung conditions in Europe,
including their perspectives on smoking-related interactions with HCPs and cessation services.
There is a growing understanding that a single “one size fits all” approach to smoking cessation with this
complex population does not work, with calls for further characterisation of this smoking population and
for a more individualised approach to their needs, and to smoking cessation in general [7, 9–13].
The objectives of this study were to explore characteristics of people across Europe with a diagnosed lung
condition and who currently smoke; their perceptions of cessation services and treatments; their
interactions with HCPs; and their recommendations for improving cessation outcomes. This study was led
by the European Lung Foundation (ELF) in collaboration with the European Respiratory Society (ERS)
Task Force on “Statement on smoking cessation on COPD and other pulmonary diseases and in smokers
with comorbidities who find it difficult to quit” [3].
Methods
Literature review
PubMED, CINAHL and keyword internet searches were used. Studies published in English, or with English
translations, exploring populations in European countries, published in 2000–2015 were included. The search
parameters were defined as: 1) lung disease; 2) current smoking; 3) smoking cessation; and 4) patient
perspectives. These included the search terms: 1) smoking-related, respiratory/lung diseases/conditions,
chronic obstructive pulmonary disease, COPD, asthma, lung cancer; 2) chronic/persistent/long-term/
involuntary/active/hardcore/recalcitrant smoking/smoker; 3) smoking cessation, stop smoking clinic, difficulty
quitting/stopping, unable to quit, hard to stop; and 4) perspectives, beliefs, perceptions, experiences.
The majority of quantitative smoking cessation and lung disease research looks at COPD, focusing on
cessation rates and clinical observations on specific treatments, with minimal feedback from the
participants in the studies [6, 14–17]. Similarly, the most relevant qualitative research comprises of small
sample size interview and questionnaire designs conducted with people with COPD [9, 18–22]. There has
been little wider investigation into common factors for people with lung diseases and transcending
European national contexts has been conducted [3, 14, 16, 23–25].
Due to the limited literature, studies on related topics were also considered: characteristics of people who
find it difficult to stop smoking; challenges to smoking cessation in people without lung conditions
[13–15, 17, 18, 20, 24–30]. Relevant factors identified were lifestyle and environment, individual smoking
experience, relationship between lung disease and smoking, desire to stop smoking and impact of repeated
cessation attempts.
The descriptor “people with a lung condition who smoke” is used throughout. Questionnaire respondents
who consented to being contacted with additional questions and entered an email address considered the
descriptor to be clear and non-judgemental.
Questionnaire
An explorative study design and sampling strategy was selected as most appropriate for gaining insight
into this hard-to-reach population. A web-based observational questionnaire was developed from the
literature review, with the questions refined by a sub-group of the ERS Task Force, including smoking
cessation and respiratory medicine clinicians, researchers and a psychologist. The 18-item questionnaire
covered four main topics: cohort characteristics; perspectives on smoking cessation; interactions with
healthcare professionals; and recommendations to improve cessation outcomes. The draft questionnaire
was reviewed by two people with lung conditions who smoke to ensure the appropriate level and tone.
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The questionnaire (see supplementary material) was available in 16 languages (English, German, French,
Spanish, Italian, Greek, Polish, Russian, Dutch, Turkish, Bulgarian, Serbian, Portuguese, Romanian,
Swedish and Norwegian). The questionnaire was open from December 2012 to March 2013. Full details of
the aim of the questionnaire, anonymity and contact details for the ELF were provided at the start of the
questionnaire, with implied consent given by each person choosing to complete the questionnaire [31].
The online format enabled rapid and wide-reaching dissemination of the questionnaire across Europe,
using existing ELF electronic communication channels, such as the ELF website with an Adwords
campaign in each language, the ELF newsletter and social media. However, this approach prevented
participation by patients without internet access at home or in their doctor’s clinic. Information and
promotional posters were also sent to ERS members and to ELF’s European patient organisation network
to share with their colleagues, patients and members.
This snowball approach to sampling, in order to reach the maximum number of potential questionnaire
respondents, facilitated the engagement of diverse patients but made it impossible to record the number of
people aware of the questionnaire and who chose not to respond [31, 32]. Furthermore, due to
inconsistency in the recording of smoking status across Europe, the potential size of the target population
is also unknown [23]. For these reasons neither the response rate nor the generalisability of the findings
relative to the size of the population could be calculated. However, the findings are validated by the
similarities between the sample and the European respiratory patient population, thus giving reliability and
generalisability to the findings and to the areas highlighted for further study.
The information entered into the anonymous questionnaire was considered truthful, as there was no
incentive for inaccurate reporting, and studies have found no statistically significant difference in patient
self-reported smoking behaviour and tobacco consumption as measured with cortisone testing [33, 34].
The data were analysed as a whole, not by country, and expressed using descriptive statistics. No
maximum/minimum number of responses for language or country was set; therefore, comparisons
between countries could not be made. Open responses were translated into English. Thematic analysis
explored commonalities. The STROBE (Strengthening the Reporting of Observational Studies in
Epidemiology) checklist for observational studies was applied [35].
Results
In total, 514 questionnaires were completed, with 490 responses from 26 European countries included in
the study. Questionnaires were excluded from 21 respondents resident outside Europe, two respondents
without diagnosed lung conditions, one person who had successfully stopped smoking, and one who did
not complete the respondent characteristic questions (numbers 15–17). The highest responses by country
were Turkey (22%), UK (21%) and Poland (20%).
Characteristics of people with lung conditions
Common respondent characteristics were: male (54%), aged 40–55 years (39%), with COPD (70%).
Asthma was the second most common condition (23%). A further 20 conditions were stated, including
tuberculosis (6%), bronchiectasis (5%), lung cancer (4%), sarcoidosis (2%) and pulmonary fibrosis (2%),
and 18 others and comorbidities (17%). Respondents could indicate more than one condition.
Levels of consumption and dependence were gauged by how much the respondents smoked per day and
how soon after waking [36]. 76% of respondents smoked 1–20 cigarettes per day (1–10, 37%; 11–20, 39%)
within 30 min of waking (61%) (⩽5 min, 23%; 6–30 min, 38%).
Impact of diagnosis on smoking behaviour was highlighted by changes in the amount smoked or
enjoyment of smoking. 59% of respondents reported smoking less since diagnosis, 34% smoked the same
amount and 7% smoked more since diagnosis. Most respondents enjoyed smoking less (52%) or to the
same extent (44%), with 4% enjoying smoking more since diagnosis.
Experiences of smoking cessation
Common reasons for continuing to smoke were: “it helps me cope with stress” (49%); “I tried to quit but
do not seem able to do it” (43%); and “I enjoy smoking” (40%) (figure 1). 10% of respondents gave
additional reasons. Habit was the most common additional reason, with catastrophic thinking evident in
some cases: “I think that if I stop smoking my world would simply collapse”. Some focused on the impact
of stress and environment, such as managing difficult family situations, isolation and boredom, or held
beliefs that inhibited cessation, such as weight loss or gain, helping loosen mucus or reduce constipation.
Others stated that it was too late or that cessation would cause an earlier death.
In the previous 12 months, 54% had made 1–5 attempts to stop smoking, 33% had made no attempts, and
4% had made >20 attempts. Different approaches to cessation were preferred, with 55% thinking that
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setting a date to stop smoking and stopping abruptly had been more successful for them, whilst 45%
thought trying to reduce smoking with cessation as a longer-term goal worked better for them. Although
the majority showed a desire to stop smoking, 90% found it “very difficult” or “difficult” to stop.
60% of the respondents had tried cessation treatments, including prescription and over-the-counter drugs,
alternative therapies and self-help resources. However, only 40% of the entire cohort of respondents
reported that these treatments helped them to stop smoking (figures 2 and 3). The most common
treatment tried was nicotine replacement therapy (NRT), such as patches, chewing gum and inhalers
(31%) (figure 2). Electronic cigarettes (e-cigarettes; 20%) and self-help books (19%) were also popular.
Additional treatments tried were identified by 12% of respondents, including will power, mouth spray
(non-NRT), chewing sweets and mints, cytisine (Tabex) and reducing smoking. 37% of respondents had
tried two or more treatments, ranging from 2–10 treatments tried.
The respondents that had tried treatments reported finding NRT (12%) and e-cigarettes (11%) the most
helpful in helping them stop smoking (figure 3). However, only 6% found self-help books helpful (figure 3).
Other treatments found helpful by 11% of respondents were cytisine (Tabex), smoking reduction, the shock
and physical impact of their diagnosis, and will power.
Interactions with HCPs
Respondents were asked when doctors or nurses had talked to them about smoking, and their expectations
and feelings about the interaction. The majority reported that doctors/nurses had talked to them about
smoking both before and after their diagnosis (41%). 31% had a conversation following diagnosis. 15%
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FIGURE 2 Smoking treatments tried (percentage of the cohort that had tried each treatment). Multiple
choices could be selected. NRT: nicotine replacement therapy.
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The most common statements were “I was hoping they could help me stop smoking” (27%), “I felt they were
nagging/lecturing” (24%), “I felt they are being helpful” (23%), “I did not think they could do much about it”
(22%), and “I was happy to discuss [smoking]” (22%). Only 9% felt that smoking was “raised too often”.
Recommendations to improve cessation outcomes
Recommendations based on six key themes are illustrated with indicative quotations.
Systemic improvement
Respondents recommended longer consultations or scheduled follow-up appointments for discussion and
monitoring of cessation attempts. Longer appointments would give HCPs time to explain the effects of
smoking, benefits of cessation for their lung condition and treatment options. For example: “an explanation
of what smoking does to your body and your lungs, plus a good proposal about how to stop smoking would
be welcome”; “give time to discuss consequences and how to cope effectively”. The respondents wanted to
feel like collaborators in their treatment, which is only possible if HCPs explain the impact of smoking on
an individual’s lung disease and outline therapy options to enable informed decision-making. Respondents
stated: “I need more information”; “giving out brochures with an explanation from the doctor, not just
putting a bundle of paper in your hands”.
A range of treatment options should be available, especially when standard treatments have not helped
achieve cessation, including alternative therapies. For example: “I have tried patches, tablets, the whole
range, nothing has worked, maybe some new approach, hypnotherapy or anything really that could help”;
“rather than discussing pharmacological agents to stop smoking, they should discuss more about the
methods which do not require pharmacological agents”.
Respondents requested access to cessation services and a specialist, including in-patient clinics and
stop-smoking courses and reduction or cessation plans. HCPs telling respondents to stop smoking without
offering further guidance or support reduced their motivation to try to stop smoking and resulted in
unsuccessful attempts. For example: “I would be elated to receive some help, rather than just being told ‘you
must give up’”; “there are lots of tips but not much practical help”.
Understanding addiction
Respondents referred to the addictive nature of tobacco and the need to treat it like alcohol and
non-prescription drug addictions. Many felt that HCPs do not adequately understand nicotine addiction
and the difficulty stopping: “I feel they could be more appreciative of how hard it is to quit… No one
wants to smoke but the fact is unfortunately we are addicted!”
Many found it hard to take advice from a doctor or nurse that they know smokes, whilst others found it difficult
to take advice from someone who does not smoke and cannot understand the addiction: “if you have never been









































































































n=17 n=14 n=12 n=8 n=7 n=5
FIGURE 3 Smoking treatments found most helpful (percentage of the cohort that found each treatment
helpful). Multiple choices could be selected. NRT: nicotine replacement therapy.
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Empathy
Respondents wanted signs of empathy, for HCPs to “show some understanding of the difficulties of giving
up smoking”. Many felt “embarrassed”, “looked down on as an addict” or treated as less intelligent: “we
are smokers NOT idiots. Yes, smoking kills us BUT WE KNOW THAT! We just find it very difficult to
stop. Don’t patronise us, consider how we feel”. One respondent summarised the message stated by many:
HCPs should “never speak dogmatically or patronisingly. Empathy and compassion in the particular
situation means there is a chance that the patient will feel more comfortable and therefore will be ready to
talk seriously about the issue”.
Individualised treatment
Respondents called for HCPs to consider their personal relationship with smoking, rather than prescribing
a standard cessation treatment: “each patient must be treated individually, not everyone is the same; as
with diseases, so with smoking, the success of the treatment involves a subjective element”. Underlying
stressors and reasons for continuing to smoke should be discussed, “find out the reasons why people don’t
stop smoking rather than putting all the emphasis on why we smoke”.
Many identified smoking as a complex psychological issue and need for holistic treatment: “to look at the
whole picture of what is going on in someone’s life—to help deal with the reasons someone smokes (i.e. as
stress relief) and then build up to a cessation attempt”. The relationship between smoking, stress and
challenging environments/circumstances was evident in the responses, with smoking maintained by “the stress
of work and my daughter”, “the severely challenging factors in my working and personal environments”.
Personal responsibility
Many respondents identified the choice to smoke and to stop as the individual’s responsibility: “Support
or drugs or counselling is needed, but it’s up to me and only me”; “the final decision rests with me and I
don’t appear to have the will power to overcome this addiction”. HCPs could discuss smoking with people
with lung conditions, providing information and a number of treatment options, alongside helping
develop the individual’s self-efficacy so that they can support themselves in cessation attempts.
Greater public awareness
Greater public awareness of the health risks of tobacco was considered a necessary early intervention to
dissuade people from starting and continuing to smoke, to “better emphasise the damage smoking does before
you get a lung disease!”. Some felt that the general population is not well-informed about tobacco-related lung
conditions and would not consider the longer-term risks when starting to smoke. Awareness-raising political
and social interventions were suggested, such as social policy to affect change, billboards advertising the
dangers of smoking, public lectures and awareness events to educate about smoking as a health problem.
Discussion
The responses to the online questionnaire are consistent with the literature on the characteristics of people
with lung conditions who smoke, and current guidelines on smoking cessation for people who find it
difficult to stop smoking [3, 8, 28, 29]. Respondents were not asked about their socio-economic or
education status. However, the open responses regarding smoking beliefs, motivation and number of quit
attempts are consistent with qualitative research into smoking in low socio-economic groups [18, 19, 34],
thus validating the study methodology used and giving generalisability to the findings and areas
highlighted for further study.
A key finding is that 67% of respondents made at least one cessation attempt in the last 12 months, and
either smoke less (59%) or enjoy smoking less (52%) since their diagnosis. This indicates a desire to stop
smoking and supports the recommendation that HCPs should frequently repeat cessation advice, as there
may be a period following diagnosis when the person is more receptive to cessation guidance [1, 3]. ERS
guidance for HCPs states that “patients with respiratory disease have a greater and more urgent need to
stop smoking than the average smoker, so respiratory physicians must take a proactive and continuing role
with all smokers in motivating them to stop” [3].
In exploring the smoking cessation experiences and recommendations of people with lung conditions who
smoke, areas for new and further research have been highlighted with reference to supporting literature,
where available (table 1). These include understanding of addiction, psychological and holistic approaches,
combinations and variety of treatments, inpatient facilities, e-cigarettes and HCP’s communication styles.
The aim of the study was achieved by providing an explorative insight into the cohort of people with lung
conditions who smoke across Europe, their perspectives of smoking cessation and interactions with HCPs.
The study has shown a motivation by people with lung conditions who smoke to use their experiences to
help improve cessation services. The questionnaire methodology was successful in reaching a hard-to-reach
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population across Europe, and has highlighted specific areas for investigation, including in national
populations or disease-specific patient sub-groups and using a dissemination approach that will track the
number of people invited to participate and produce a response rate. By building on the findings of this
study the recommendations and experiences of people with lung conditions who still smoke can be used
to inform individual services, national smoking cessation strategies and European guidelines to achieve
more successful cessation attempts.
Acknowledgements
We would like to thank the European Respiratory Society and the Task Force on “Consensus on smoking cessation on
COPD and other pulmonary diseases” for supporting the European Lung Foundation (ELF) in conducting this study to
explore patient perspectives in smoking cessation. ELF would also like to thank everyone who completed the online
questionnaire and provided additional recommendations and feedback on their experiences.
References
1 Tønnesen P. Tobacco smoking. In: Gibson GJ, Loddenkemper R, Sibille Y, et al., eds. European Lung White Book.
2nd Edn. Sheffield, European Respiratory Society, 2013.
2 Underner M, Perriot J, Peiffer G. Smoking cessation in smokers with chronic obstructive pulmonary disease.
Rev Mal Respir 2014; 31: 937–960.
3 Jiménez-Ruiz CA, Andreas S, Lewis KE, et al. Statement on smoking cessation in COPD and other pulmonary
diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J 2015; 46: 61–79.
4 Raupach T, Quintel M, Hinterthaner M. Preoperative smoking cessation in patients with lung cancer. Pneumologie
2010; 64: 694–700.
TABLE 1 Recommendations to improve smoking cessation outcomes with supporting
literature, where available
Respondent recommendations References for supporting literature
It is important for the healthcare professional to understand
each person’s level of addiction and the high level of
challenge in attempting to stop smoking
[6, 18, 25]
Frequently repeat cessation advice and plan follow-up visits
to address smoking cessation as the primary issue
[19, 27]
Discussing reasons for relapse can provide important
information for tailoring individual treatments
[10, 13, 14, 18]
Self-efficacy and self-esteem affect the individual’s ability to
stop smoking, so advice should be targeted to address
issues of motivation, self-efficacy and self-esteem
[3, 10, 11, 26–28]
Pharmacological and psychological support should be
provided as part of smoking cessation treatment due to
the frequency of anxiety, depression and panic disorders
[3, 7, 11, 14, 16, 17, 26]
Healthcare professionals should be empathic, understanding
and show respect to the individual’s opinions about
smoking
[17–27]
If a certain treatment does not help, offer a new or different
cessation treatment
[7, 17, 28]
People who find it especially difficult to stop smoking due to
their home environment could benefit from intensive
treatment, such as in an inpatient cessation facility for an
agreed period of time
[12]
If someone finds it difficult to stop smoking abruptly, i.e.
“going cold turkey”, suggest a reduction programme over
an agreed period of time
[3, 34]
Earlier public and individual intervention, such as public
awareness initiatives, and routine discussion of smoking is
needed, especially before a lung disease has developed
[8, 20]
Allow time to discuss the individual’s relationship with
smoking and reasons for continuing
[13]
Give constructive advice on cessation strategies and support
Give a range of treatment options, and explain them so that
each person can make an informed decision about their
treatment
Explain the effect of smoking and how stopping would affect
each person’s lung condition
ERJ Open Res 2016; 2: 00009-2016 | DOI: 10.1183/23120541.00009-2016 7
SMOKING CESSATION | S. MASEFIELD ET AL.
5 Thomson NC, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 2009; 15:
39–45.
6 Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and Management of Stable Chronic Obstructive Pulmonary
Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest
Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179–191.
7 Jones D. Chronic obstructive pulmonary disease part 1: smoking cessation. Nurs Stand 2015; 29: 52–57.
8 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic
Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD 2016.
www.goldcopd.org/uploads/users/files/GOLD_Report%202016.pdf Date last updated: December, 2015. Date last
accessed: January 15, 2016.
9 Eklund BM, Nilsson S, Hedman L, et al. Why do smokers diagnosed with COPD not quit smoking? A qualitative
study. Tob Induc Dis 2012; 10: 17.
10 Yap SY, Lunn S, Pang E, et al. A psychological intervention for smoking cessation delivered as treatment for
smokers with chronic obstructive pulmonary disease: Multiple needs of a complex group and recommendations
for novel service development. Chron Respir Dis 2015; 12: 230–237.
11 van Eerd EA, van Rossem CR, Spigt MG, et al. Do we need tailored smoking cessation interventions for smokers
with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco
smoking. Respiration 2015; 90: 211–219.
12 Gratziou C, Florou A, Ischaki E, et al. Smoking cessation effectiveness in smokers with COPD and asthma under
real life conditions. Respir Med 2014; 108: 577–583.
13 Ritchie D, Schulz S, Bryce A. One size fits all? A process evaluation – the turn of the ‘story’ in smoking cessation.
Public Health 2007; 121: 341–348.
14 Coronini-Cronberg S, Heffernan C, Robinson M. Effective smoking cessation interventions for COPD patients:
a review of the evidence. JRSM Short Reports 2011; 2: 78.
15 Strong DR, Leventhal AM, Evatt DP, et al. Positive reactions to tobacco predict relapse after cessation. J Abnorm
Psychol 2011; 120: 999–1005.
16 Balmford J, Borland R, Hammond D, et al. Adherence to and reasons for premature discontinuation from
stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res 2011; 13: 94–102.
17 Jones D. Chronic obstructive pulmonary disease part 2: non-pharmacological therapy. Nurs Stand 2015; 29: 53–58.
18 Medbø A, Melbye H, Rudebeck CE. “I did not intend to stop. I just could not stand cigarettes anymore.”
A qualitative interview study of smoking cessation among the elderly. BMC Fam Pract 2011; 12: 42.
19 Walters JA, Cameron-Tucker H, Courtney-Pratt H, et al. Supporting health behaviour change in chronic
obstructive pulmonary disease with telephone health-mentoring: insights from a qualitative study. BMC Fam Pract
2012; 13: 55.
20 Bethea J, Murtagh B, Wallace SE. “I don’t mind damaging my own body” a qualitative study of the factors that
motivate smokers to quit. BMC Public Health 2015; 15: 4.
21 Schofield I, Kerr S, Tolson D. An exploration of the smoking-related health beliefs of older people with chronic
obstructive pulmonary disease. J Clin Nurs 2007; 16: 1726–1735.
22 Wilson JS, Elborn JS, Fitzsimons D. ‘It’s not worth stopping now’: why do smokers with chronic obstructive
pulmonary disease continue to smoke? A qualitative study. J Clin Nurs 2011; 20: 819–827.
23 Bogdanovica I, Godfrey F, McNeill A, et al. Research paper. Smoking prevalence in the European Union:
a comparison of national and transnational prevalence survey methods and results. Tob Control 2011; 20: e4.
24 Borland R, Yong HH, Balmford J, et al. Motivational factors predict quit attempts but not maintenance of smoking
cessation: findings from the International Tobacco Control Four country project. Nicotine Tob Res 2010; 12: 4–11.
25 Vangeli E, Stapleton J, Smit ES, et al. Predictors of attempts to stop smoking and their success in adult general
population samples: a systematic review. Addiction 2011; 106: 2110–2121.
26 Kerr S, Watson H, Tolson D, et al. Smoking after the age of 65 years: a qualitative exploration of older current
and former smokers’ views on smoking, stopping smoking, and smoking cessation resources and services. Health
Social Care Community 2006; 14: 572–582.
27 Argüder E, Hasanoğlu HC, Karalezli A, et al. Factors that increasing tendency to smoking cessation. TuberkToraks
2012; 60: 129–135.
28 Zernig G, Wallner R, Grohs U, et al. ‘A randomized trial of short psychotherapy versus sustained-release
bupropion for smoking cessation.’ Addiction 2008; 103: 2024–2031.
29 Marino MG, Fusconi E, Magnatta R, et al. Epidemiologic determinants affecting cigarette smoking cessation: a
retrospective study in a National Health System (SSN) treatment service in Rome (Italy). J Environ Public Health
2010; 2010: 183206.
30 Wang D, Connock M, Barton P, et al. ‘Cut down to quit’ with nicotine replacement therapies in smoking
cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess 2008; 12: 1–135.
31 Bowling A. Research Methods in Health: Investigating Health and Health Services. 4th Edn. Maidenhead, Open
University Press, 2014.
32 Shaghaghi A, Bhopal RS, Sheikh A. Approaches to recruiting ‘hard-to-reach’ populations into research: a review of
the literature. Health Promot Perspect 2011; 1: 86–94.
33 Ramo DE, Hall SM, Prochaska JJ. Reliability and validity of self-reported smoking in an anonymous online survey
with young adults. Health Psychol 2011; 30: 693–701.
34 Studts JL, Ghate SR, Gill JL, et al. Validity of self-reported smoking status among participants in a lung cancer
screening trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1825–1828.
35 Von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol
2008; 61: 344–349.
36 Fagerström K, Furberg H. A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence
across countries. Addiction 2008; 103: 841–846.
ERJ Open Res 2016; 2: 00009-2016 | DOI: 10.1183/23120541.00009-2016 8
SMOKING CESSATION | S. MASEFIELD ET AL.
